FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Bill Aims to Prevent Brand Drug Firms Blocking Generic Entrants

Senator Patrick Leahy (D-VT) introduces legislation to combat anticompetitive practices used by some brand-name pharmaceutical and biologic companies ...

Human Drugs

Lupin Form 483 Released After Inspection

FDA posts a three-item Form 483 after an inspection at Lupins Goa, India drug manufacturing facility found GMP problems.

Federal Register

Pediatric Panels to Review Duchenne Trial Protocol

Federal Register notice: FDA announces a 5/18 joint Pediatric Advisory Committee and Pediatric Ethics Subcommittee meeting to discuss a referral by an...

Federal Register

FDA Seeks Comments on GLP Recordkeeping

Federal Register notice: FDA seeks comments on an information collection extension for Good Laboratory Practice Regulations for Nonclinical Studies 2...

Medical Devices

New Web Page on Symbols in Device Labeling

FDA launches a new medical device Web page, Use of Symbols in Labeling, to assist the public in understanding the Use of Symbols in Labeling final rul...

Medical Devices

FDA Clears Breast Lesion Finder

FDA clears a Faxitron 510(k) for the LOCalizer, a wireless radiofrequency identification breast lesion localization system.

Human Drugs

Radius Health NDA Approved for Osteoporosis

FDA approves a Radius Health NDA for Tymlos (abaloparatide) injection for treating postmenopausal women with osteoporosis at high risk for fracture.

Federal Register

Conference for Small Business Industry Assistance

Federal Register notice: CDER and CDRH announce a two-day (5/9-10) public conference entitled FDA Small Business and Industry Assistance Regulatory Ed...

Human Drugs

FDA Expands Bayer Drug for Liver Cancer Use

FDA expands the use of Bayers Stivarga (regorafinib) to include treating patients with hepatocellular carcinoma who have been previously treated with ...

Human Drugs

Amgen, Sandoz Argue Biosim Issues at Supreme Court

Amgen and Sandoz argue their differing views on requirements of the Biologics Price Competition and Innovation Act involving Neupogen exclusivity befo...